GSK Expects Vaccine Approval in First Half of 2021

The transcript discusses the development and approval timeline for the GSK Sanofi vaccine, highlighting the critical clinical trials and expected approval in the first half of 2021. It explains the allocation of US funding for research, development, and manufacturing scale-up. GSK's approach to pricing, profit reinvestment, and ensuring global vaccine accessibility is outlined. The manufacturing process, including scaling up production capacity across the US, Canada, and Europe, is detailed. Finally, the strategy for vaccine allocation and the importance of regulatory approval in different countries are discussed.

What is the significance of investing in pandemic preparedness according to the discussion?

Where are the manufacturing sites for the vaccine located?